Circio announces publication of two abstracts...

Circio Holding ASA (OSE: CRNA), a biotechnology company based in Norway, announced the publication of two abstracts accepted for presentation at the 2026 American Society of Gene and Cell Therapy (ASGCT) annual meeting in Boston. One abstract was selected for an oral presentation on 15 May 2026, and the other for a poster presentation on 13 May 2026. The presentations will showcase Circio's circular RNA-based gene expression technology, circVec, which has demonstrated up to 40-fold enhanced gene expression and 75-fold increased RNA half-life compared to conventional mRNA-based systems. The company claims its technology has the potential to transform conventional AAV gene therapy and become a new gold-standard gene expression technology. The materials will be made available on the Circio website after the ASGCT presentations.

Circio Holding ASA: Cancellation of Subsequen...

Circio Holding ASA announced the cancellation of its planned Subsequent Offering, which was initially intended to raise up to NOK 82.5 million through the issuance of up to 7,638,888 new shares at the same subscription price as a prior Private Placement. The Private Placement had previously allocated 23,148,148 new shares, raising gross proceeds of approximately NOK 250 million. The cancellation was due to the Company's shares trading below the subscription price, allowing shareholders to acquire shares at lower prices and reduce dilution. The decision is disclosed in accordance with section 5-12 of the Norwegian Securities Trading Act.

0RIS